Suchergebnisse - Sebag, Michael

Atypical femur fracture in a woman with osteogenesis imperfecta and multiple myeloma von Chen, Yuxi, Sebag, Michael, Powell, Thomas I., Morin, Suzanne N.

Volltext Volltext

Practical Approaches to the Use of Lenalidomide in Multiple Myeloma: A Canadian Consensus von Reece, Donna, Kouroukis, C. Tom, LeBlanc, Richard, Sebag, Michael, Song, Kevin, Ashkenas, John

Volltext Volltext Volltext

Translation initiation factor eIF4F modifies the dexamethasone response in multiple myeloma von Robert, Francis, Roman, William, Bramoullé, Alexandre, Fellmann, Christof, Roulston, Anne, Shustik, Chaim, Porco, John A., Shore, Gordon C., Sebag, Michael, Pelletier, Jerry

Volltext Volltext Volltext

Oxo-aglaiastatin-Mediated Inhibition of Translation Initiation von Itoua Maïga, Rayelle, Cencic, Regina, Chu, Jennifer, Waller, Daniel D., Brown, Lauren E., Devine, William G., Zhang, Wenhan, Sebag, Michael, Porco Jr., John A., Pelletier, Jerry

Volltext Volltext Volltext

Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity von Tiedemann, Rodger E., Mao, Xinliang, Shi, Chang-Xin, Zhu, Yuan Xiao, Palmer, Stephen E., Sebag, Michael, Marler, Ron, Chesi, Marta, Fonseca, Rafael, Bergsagel, P. Leif, Schimmer, Aaron D., Stewart, A. Keith

Volltext Volltext Volltext

Longitudinal single-cell analysis of a myeloma mouse model identifies subclonal molecular programs associated with progression von Croucher, Danielle C., Richards, Laura M., Tsofack, Serges P., Waller, Daniel, Li, Zhihua, Wei, Ellen Nong, Huang, Xian Fang, Chesi, Marta, Bergsagel, P. Leif, Sebag, Michael, Pugh, Trevor J., Trudel, Suzanne

Volltext Volltext Volltext

AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies von Chesi, Marta, Robbiani, Davide F., Sebag, Michael, Chng, Wee Joo, Affer, Maurizio, Tiedemann, Rodger, Valdez, Riccardo, Palmer, Stephen E., Haas, Stephanie S., Stewart, A. Keith, Fonseca, Rafael, Kremer, Richard, Cattoretti, Giorgio, Bergsagel, P. Leif

Volltext Volltext Volltext

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma von Bahlis, Nizar J., Sutherland, Heather, White, Darrell, Sebag, Michael, Lentzsch, Suzanne, Kotb, Rami, Venner, Christopher P., Gasparetto, Cristina, Del Col, Aldo, Neri, Paola, Reece, Donna, Kauffman, Michael, Shacham, Sharon, Unger, T. J., Jeha, Jacqueline, Saint-Martin, Jean-Richard, Shah, Jatin, Chen, Christine

Volltext Volltext Volltext

Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure von Siegel, David S., Schiller, Gary J., Song, Kevin W., Agajanian, Richy, Stockerl‐Goldstein, Keith, Kaya, Hakan, Sebag, Michael, Samaras, Christy, Malek, Ehsan, Talamo, Giampaolo, Seet, Christopher S., Mouro, Jorge, Pierceall, William E., Zafar, Faiza, Chung, Weiyuan, Srinivasan, Shankar, Agarwal, Amit, Bahlis, Nizar J.

Volltext Volltext Volltext

Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database von McCurdy, Arleigh, Venner, Christopher P., Masih-Khan, Esther, Louzada, Martha, LeBlanc, Richard, Sebag, Michael, Song, Kevin, Jimenez-Zepeda, Victor H., Kotb, Rami, Kardjadj, Moustafa, Mian, Hira, White, Darrell, Stakiw, Julie, Aslam, Muhammad, Reiman, Anthony, Gul, Engin, Reece, Donna

Volltext Volltext Volltext

The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database von Cherniawsky, Hannah M., Kukreti, Vishal, Reece, Donna, Masih-Khan, Esther, McCurdy, Arleigh, Jimenez-Zepeda, Victor H., Sebag, Michael, Song, Kevin, White, Darrell, Stakiw, Julie, LeBlanc, Richard, Reiman, Anthony, Aslam, Muhammad, Louzada, Martha, Kotb, Rami, Gul, Engin, Atenafu, Eshetu, Venner, Christopher P.

Volltext Volltext Volltext

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment von Siegel, David S., Schiller, Gary J., Samaras, Christy, Sebag, Michael, Berdeja, Jesus, Ganguly, Siddhartha, Matous, Jeffrey, Song, Kevin, Seet, Christopher S., Talamo, Giampaolo, Acosta-Rivera, Mirelis, Bar, Michael, Quick, Donald, Anz, Bertrand, Fonseca, Gustavo, Reece, Donna, Pierceall, William E., Chung, Weiyuan, Zafar, Faiza, Agarwal, Amit, Bahlis, Nizar J.

Volltext Volltext Volltext

Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis von Mian, Hira, Eisfeld, Christine, Venner, Christopher P., Masih-Khan, Esther, Kardjadj, Moustafa, Jimenez-Zepeda, Victor H., Khandanpour, Cyrus, Lenz, Georg, McCurdy, Arleigh, Sebag, Michael, Song, Kevin, LeBlanc, Richard, White, Darrell, Stakiw, Julie, Reiman, Anthony, Louzada, Martha, Aslam, Muhammad, Kotb, Rami, Gul, Engin, Reece, Donna

Volltext Volltext Volltext

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma von Gasparetto, Cristina, Lentzsch, Suzanne, Schiller, Gary, Callander, Natalie, Tuchman, Sascha, Chen, Christine, White, Darrell, Kotb, Rami, Sutherland, Heather, Sebag, Michael, Baljevic, Muhamed, Bensinger, William, LeBlanc, Richard, Venner, Chris, Bahlis, Nizar, Rossi, Adriana, Biran, Noa, Sheehan, Heidi, Saint‐Martin, Jean‐Richard, Van Domelen, Dane, Kai, Kazuharu, Shah, Jatin, Shacham, Sharon, Kauffman, Michael, Lipe, Brea

Volltext Volltext Volltext

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma von Vij, Ravi, Wang, Michael, Kaufman, Jonathan L., Lonial, Sagar, Jakubowiak, Andrzej J., Stewart, A. Keith, Kukreti, Vishal, Jagannath, Sundar, McDonagh, Kevin T., Alsina, Melissa, Bahlis, Nizar J., Reu, Frederic J., Gabrail, Nashat Y., Belch, Andrew, Matous, Jeffrey V., Lee, Peter, Rosen, Peter, Sebag, Michael, Vesole, David H., Kunkel, Lori A., Wear, Sandra M., Wong, Alvin F., Orlowski, Robert Z., Siegel, David S.

Volltext Volltext Volltext

Promiscuous Mutations Activate the Non-Canonical NF-kB Pathway in Multiple Myeloma von Keats, Jonathan J., Fonseca, Rafael, Chesi, Marta, Schop, Roelandt, Baker, Angela, Chng, Wee-Joo, Van Wier, Scott, Tiedemann, Rodger, Shi, Chang-Xin, Sebag, Michael, Braggio, Esteban, Henry, Travis, Zhu, Yuan-Xiao, Fogle, Homer, Price-Troska, Tammy, Ahmann, Gregory, Mancini, Catherine, Brents, Leslie A., Kumar, Shaji, Greipp, Philip, Dispenzieri, Angela, Bryant, Barb, Mulligan, George, Bruhn, Laurakay, Barrett, Michael, Valdez, Riccardo, Trent, Jeff, Stewart, A. Keith, Carpten, John, Bergsagel, P. Leif

Volltext Volltext Volltext

Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients von Gasparetto, Cristina, Schiller, Gary J., Tuchman, Sascha A., Callander, Natalie S., Baljevic, Muhamed, Lentzsch, Suzanne, Rossi, Adriana C., Kotb, Rami, White, Darrell, Bahlis, Nizar J., Chen, Christine I., Sutherland, Heather J., Madan, Sumit, LeBlanc, Richard, Sebag, Michael, Venner, Christopher P., Bensinger, William I., Biran, Noa, Ammu, Sonia, Ben-Shahar, Osnat, DeCastro, Andrew, Van Domelen, Dane, Zhou, Tianjun, Zhang, Chris, Bentur, Ohad S., Shah, Jatin, Shacham, Sharon, Kauffman, Michael, Lipe, Brea

Volltext Volltext Volltext